Twenty-Eight Health Pricing Analysis & Total Cost

What Twenty-Eight Health Actually Charges

The platform operates on a straightforward fee structure: $25 per asynchronous clinician consultation for uninsured patients, with $0 copay visits for those with accepted insurance. This positions it below the national median telehealth visit cost of $40, $80 reported in the 2023 FAIR Health consumer cost data [1]. Medication pricing depends entirely on whether a patient has pharmacy benefits.

For cash-pay patients selecting generic combined oral contraceptives (COCs), monthly costs range from $9 to $50. The ACA mandates that most commercial insurance plans cover FDA-approved contraceptives without cost-sharing [2], which means insured patients on the platform typically pay $0 for generic pills. Twenty-Eight Health's niche is serving patients who face access barriers: those on Medicaid, those without a regular provider, or those in contraception deserts. A 2020 Power to Decide analysis found that 19 million U.S. women lived in contraceptive deserts with limited access to full-range contraceptive services [3].

The platform does not charge subscription fees. Patients pay per consultation, and prescriptions route to partner pharmacies or ship directly. This contrasts with competitors like Nurx and SimpleHealth, which may bundle monthly subscription costs into their pricing.

Medication Costs by Category

Generic levonorgestrel/ethinyl estradiol combinations represent the lowest-cost tier at $9, $15/month for cash-pay patients. The progestin-only pill (norethindrone 0.35 mg) sits in a similar range [4]. These align with GoodRx national average pricing for tier-1 generics.

The vaginal ring (etonogestrel/ethinyl estradiol, generic for NuvaRing) costs $15, $80/month depending on coverage. Brand NuvaRing without insurance runs $150+ monthly. The injectable depot medroxyprogesterone acetate (DMPA) costs approximately $25, $100 per quarter through cash-pay pharmacy pricing [5]. Twenty-Eight Health can prescribe DMPA for self-injection at home, which eliminates the in-office administration fee that typically adds $20, $40.

Emergency contraception (levonorgestrel 1.5 mg) is available through the platform at $20, $50. The FDA approved over-the-counter sales of levonorgestrel emergency contraception without age restrictions in 2013 [6], but Twenty-Eight Health offers prescription-grade access and clinical follow-up that OTC purchase lacks.

For UTI treatment, a consultation plus a 3-day course of nitrofurantoin or trimethoprim-sulfamethoxazole runs approximately $25 (visit) plus $4, $15 (generic antibiotic). The Infectious Diseases Society of America guidelines recommend nitrofurantoin as first-line for uncomplicated UTI [7].

Insurance and Medicaid Acceptance

Twenty-Eight Health differentiates itself through Medicaid acceptance, a feature most direct-to-consumer telehealth contraception platforms lack. The platform accepts Medicaid in multiple operating states, which is significant given that Medicaid finances 75% of publicly funded family planning services in the United States [8].

Under ACA Section 2713, non-grandfathered commercial plans must cover all FDA-cleared contraceptive methods without cost-sharing when prescribed by an in-network provider [2]. Twenty-Eight Health's clinicians are credentialed with select insurers, enabling this $0 copay pathway. Patients should verify network status before their visit, as out-of-network consultations default to the $25 cash rate.

A 2021 analysis in Contraception found that telehealth contraception prescribing expanded access for patients in rural counties, with 68% of telehealth contraceptive users reporting it as their first interaction with reproductive health services in over a year [9]. This suggests the platform's pricing model removes financial friction for a population that might otherwise delay care.

Total Annual Cost Scenarios

For an uninsured patient using generic COCs with two consultations per year (initial plus one follow-up), the annual total is approximately $158, $650:

Scenario A (lowest cost): $25 (visit) × 2 + $9/month × 12 = $158/year. Scenario B (mid-range, ring user): $25 × 2 + $45/month × 12 = $590/year. Scenario C (injectable DMPA): $25 × 2 + $75/quarter × 4 = $350/year.

For an insured patient with Medicaid or accepted commercial coverage: $0 visits + $0 generic medication = $0/year. The ACA contraceptive coverage mandate eliminates out-of-pocket expenses for the majority of insured patients using generic methods [10].

These figures exclude optional STI screening panels ($50, $150 depending on panel scope) and emergency contraception (situational). Lab work for STI screening ordered through the platform routes to partner labs, with pricing variable by insurance status and geographic region.

Is Twenty-Eight Health Legitimate?

Twenty-Eight Health operates with licensed clinicians (MDs, NPs, PAs) credentialed in each state where they prescribe. The platform launched in 2020 with explicit focus on reproductive health equity, targeting communities underserved by traditional healthcare infrastructure. Its clinical model aligns with ACOG Committee Opinion 788, which supports pharmacist and telehealth prescribing of hormonal contraception to reduce access barriers [11].

The platform uses asynchronous consultations for straightforward contraceptive prescribing. This model mirrors what the CDC's U.S. Selected Practice Recommendations (US SPR) endorse: for most healthy individuals, combined hormonal contraceptives can be initiated after a medical history screen without requiring a physical exam or lab tests [12]. Blood pressure measurement remains recommended before COC initiation, but the US SPR acknowledges that self-reported blood pressure is acceptable in telehealth contexts.

No FDA enforcement actions, state medical board sanctions, or FTC complaints appear in public records against Twenty-Eight Health as of May 2025. The company has received funding from organizations focused on health equity, including partnerships with reproductive justice nonprofits.

Twenty-Eight Health vs. Competitors

Compared to Nurx ($0, $75/consultation, $15/month delivery fee for some plans), Twenty-Eight Health's flat $25 visit fee is transparent but potentially higher for insured patients who would pay $0 through Nurx's insurance billing. SimpleHealth charges $20/month as a membership that includes consultations, making it cheaper for frequent users but more expensive for those needing only annual renewals.

The Pill Club (now Favor) historically offered $0 pricing for insured patients with free delivery, operating on insurance reimbursement margins. Planned Parenthood Direct app charges $25, $50 per visit with sliding-scale options.

Where Twenty-Eight Health distinguishes itself is Medicaid acceptance and focus on populations facing the greatest access gaps. A 2022 study in JAMA Network Open found that telehealth contraception services disproportionately benefited patients in areas with OB-GYN shortages, with 41% of users residing in Health Professional Shortage Areas [13]. Twenty-Eight Health explicitly targets this demographic.

For patients weighing cost alone, the platform ranks mid-tier. For patients prioritizing Medicaid compatibility, multilingual support, and reproductive justice orientation, it occupies a distinct niche that competitors have not fully replicated.

Clinical Scope and Limitations

Twenty-Eight Health prescribes combined oral contraceptives, progestin-only pills, the contraceptive patch, vaginal ring, DMPA injection, and emergency contraception. It also treats uncomplicated UTIs and offers STI screening referrals. It does not prescribe IUDs or implants (these require in-person insertion), and it does not manage complex gynecologic conditions.

The WHO Medical Eligibility Criteria for Contraceptive Use (MEC) categorize most hormonal methods as Category 1 (no restriction) or Category 2 (advantages generally outweigh risks) for healthy individuals aged 18, 40 without cardiovascular risk factors [14]. Twenty-Eight Health's screening questionnaire mirrors MEC category assessments, flagging patients with Category 3 or 4 conditions (migraines with aura, uncontrolled hypertension, active liver disease) for referral rather than telehealth prescribing.

This scope limitation is clinically appropriate. ACOG Practice Bulletin 206 notes that for women without contraindications, self-screening questionnaires demonstrate high concordance with clinician assessment for hormonal contraceptive eligibility [15]. The platform's clinical guardrails appear consistent with national guidelines.

Reproductive Health Outcomes Data

No peer-reviewed studies have evaluated Twenty-Eight Health's specific clinical outcomes or patient satisfaction data in published literature as of May 2025. This is not unusual for a platform of its age and scale.

Broader evidence supports telehealth contraception prescribing efficacy. A 2023 systematic review in Contraception: X analyzed 14 studies of direct-to-patient telehealth contraception services and found continuation rates of 70 to 82% at 12 months, comparable to in-person prescribing [16]. Method satisfaction scores were equivalent between telehealth and clinic-based initiation across studies.

The contraceptive failure rate for typical use of COCs remains approximately 7% per year according to Trussell's estimates published in Contraceptive Technology [17]. This failure rate is method-dependent, not platform-dependent. Perfect-use failure rates for COCs drop to 0.3% annually. Twenty-Eight Health's prescribing of standard FDA-approved formulations means expected efficacy matches published data regardless of the prescribing channel.

For DMPA, typical-use failure is 4% annually, and the self-injection formulation (Depo-subQ Provera 104) shows equivalent efficacy to clinician-administered injection in a randomized trial (N=537) published in Contraception [18].

When the Platform May Not Be Cost-Effective

Patients with comprehensive commercial insurance and an established OB-GYN relationship may find no cost advantage. Their existing provider can prescribe 12-month supplies with $0 copay under ACA mandates, often with same-day in-office initiation.

Patients seeking long-acting reversible contraception (IUDs, implants) cannot complete their care through Twenty-Eight Health. LARC methods carry higher upfront cost ($0, $1,300 depending on insurance) but lower 5-year total cost and superior efficacy. The levonorgestrel IUD (Mirena) has a typical-use failure rate of 0.2% over 5 years [17], making it the most cost-effective option for patients committed to long-term prevention.

Patients requiring frequent follow-up (e.g., those trialing multiple methods due to side effects) will accumulate $25 per-visit charges that could exceed a subscription model competitor. Three visits in a year totals $75 in consultation fees alone before medication costs.